Evidence map›Paper›PMID 27647699›Full record

ArticleThe American journal on addictions2016

Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.

Ayesha Sajid, Aaron Whiteman, Richard L Bell, Marion S Greene, Eric A Engleman, R Andrew Chambers

Open access · bronzeAbstract read
In one paragraph

Article in The American journal on addictions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Systematic Literature Review of Prescription Drug Monitoring Programs.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2018
    Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ayesha SajidDepartment of Psychiatry, Indiana University School of Medicine, Indianapoils, Indiana.
Aaron WhitemanDepartment of Psychiatry, Indiana University School of Medicine, Indianapoils, Indiana.
Richard L BellDepartment of Psychiatry, Indiana University School of Medicine, Indianapoils, Indiana.
Marion S GreeneFairbanks School of Public Health, IUPUI, Indianapolis, Indiana.
Eric A EnglemanDepartment of Psychiatry, Indiana University School of Medicine, Indianapoils, Indiana.
R Andrew ChambersDepartment of Psychiatry, Indiana University School of Medicine, Indianapoils, Indiana. robchamb@iupui.edu.
Indiana University · USIndiana University School of MedicinePancur Kasih Association · ID

Funding

Consequences of voluntary intake of ethanol & nicotine during peri-adolescenceR01AA020396 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI BELL, RICHARD LOWELL, ENGLEMAN, ERIC A. · 2012 to 2016
$1.2M
NIAAA NIH HHS R01 AA020396
6 · The paper itself

Abstract

BACKGROUND AND

objectivesFourfold increases in opioid prescribing and dispensations over 2 decades in the U.S. has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies. This study examines Prescription Drug Monitoring Program (PDMP) tracking as a novel measure of opioid addiction treatment outcomes in a university-affiliated integrated mental health-addiction treatment clinic.

methodsRepeated measure parametrics examined PDMP and urine drug screening (UDS) data before and after first injection for all patients (N = 68) who received at least one long-acting naltrexone injection (380 mg/IM) according to diagnostic groupings of having either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and opioid use disorders.

resultsThere were no group differences post-injection in treatment days, injections delivered, or treatment service encounters. UDS and PDMP measures of opioid exposures were greater in opioid compared to alcohol-only patients. Post-first injection, UDS's positive for opioids declined (p < .05) along with PDMP measures of opioid prescriptions (p < .001), doses (p < .01), types (p < .001), numbers of dispensing prescribers (p < .001) and pharmacies (p < .001). Opioid patients without alcohol disorders showed the best outcomes with 50% to 80% reductions in PDMP-measures of opioids, down to levels of alcohol-only patients.

conclusionsThis study shows PDMP utility for measuring opioid addiction treatment outcomes, supporting the routine use of PDMPs in clinical and research settings. SCIENTIFIC SIGNIFICANCE: These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients. (Am J Addict 2016;25:557-564).

Indexed as

Prescription Drug Monitoring ProgramsAdultAlcohol-Related DisordersAnalgesics, OpioidDiagnosis, Dual (Psychiatry)FemaleHumansInjections, IntravenousLongitudinal StudiesMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersSubstance Abuse DetectionTreatment OutcomeAnalgesics, OpioidNaltrexoneNarcotic Antagonists

Identifiers

PMID27647699
PMCPMC5096257
OpenAlexW2521992048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.